Scientists have developed the world’s first plant-based vaccine, while Canada has become the first country to allow the vaccine.
Medicago’s 2-dose vaccine could be given to adults between 18 and 64, Canadian regulators said Thursday, but said there was little data on shots in people aged 65 and over. Available.
These companies include Medicago, a subsidiary of Mitsubishi Chemical Holdings Corporation of Japan, GlaxoSmithKline, a British company, and Philip Morris International, a Swiss-American company.
Experts say the plant-derived vaccine has been dubbed protein, experts say, and it is easier to deliver and store than an mRNA vaccine because it does not need to be kept at a shallow temperature. That is why this vaccine will be easier and less expensive to import and export.
According to experts, the vaccine is made from proteins found in plants that make the immune system look like the coronavirus to be prepared to fight it and boost the immune system’s response to the vaccine. In addition, a unique pandemic adjuvant of GlaxoSmithKline has also been used.
According to the report, an agreement has been reached to supply 76 million vaccine doses to Canada. At the same time, Medicago is also in talks with other countries to protect against various coronavirus strains. Up to 71% effective.
